10 results about "Neointimal hyperplasia" patented technology

Devices and methods can be used to treat heart conditions, hypertension, and other medical disorders. For example, devices and methods for treating atrial fibrillation by performing thoracic vein ablation procedures, including pulmonary vein myocardium ablation are described herein. In some embodiments, the ablation is performed in coordination with the delivery a pharmacological agent that can abate the formation of tissue stenosis or neointimal hyperplasia caused by the ablation.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The disclosure relates to compositions and methods for reducing SMAD3 expression in a blood vessel in a patient in need thereof. Also provided herein are compositions and methods for reducing blood vessel graft stenosis in a subject, preventing occlusion of a blood vessel or a blood vessel graft, reducing neointimal hyperplasia in a blood vessel or a blood vessel graft, increasing endothelization in a blood vessel or a blood vessel graft, increasing patency in a blood vessel or a blood vessel graft, reducing endothelial to mesenchymal transition (EndMT) in a blood vessel or a blood vessel graft, reducing thrombosis in in a blood vessel or a blood vessel graft and / or reducing TGF-beta signaling in a blood vessel or a blood vessel graft. In embodiments, the patient is undergoing arterio-venous fistula (AVF) surgery.

To provide a heterocyclic compound and its use.SOLUTION: Provided herein are novel heterocyclic compounds, e.g., compounds having Formula I, I-P, II, II-P, III, or IV. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in the inhibition of aldehyde dehydrogenase, retinoid pathway activation, and / or to treat various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH), or neointimal hyperplasia (NIH), or as a male contraceptive.SELECTED DRAWING: Figure 1A

The invention relates to application of lindelactone in preparation of a medicine for inhibiting neointimal hyperplasia in blood vessels. Based on the natural source and biological activity of the lindelactone, the invention develops a pharmaceutical molecule with application prospects, and the lindelactone can be used for preventing and / or treating endometrial neogenesis, and is especially suitable for intervention of interventional postoperative restenosis. The linderane is used for preventing neointimal neogenesis by inhibiting abnormal proliferation and migration of vascular smooth muscle cells. Experimental data show that lindelactone does not show obvious systemic toxicity under the treatment dosage and has lower potential of side effects. The lindelinolide provides parameter data for preparation of the medicine for inhibiting endovascular neointimal hyperplasia, is expected to be applied to percutaneous coronary intervention postoperative complications, especially prevention and treatment of stent restenosis, and can become a potential medicine for intervening in restenosis.

Devices and methods can be used to treat of heart conditions, hypertension, and other medical disorders. For example, devices and methods for treating atrial fibrillation by performing thoracic vein ablation procedures, including pulmonary vein myocardium ablation are described herein. In some embodiments, the ablation is performed in coordination with the delivery a pharmacological agent that can abate the formation of tissue stenosis or neointimal hyperplasia caused by the ablation.

The application relates to the technical field of medical devices, in particular to a spring stent, a stent catheter system and a stent implantation method. The spring stent provided by the application comprises a clockwork spring, the clockwork spring comprises a hollow cylinder which is spirally wound by a memory alloy wire mesh ring, the memory alloy wire mesh is kept flush at both ends of the hollow cylinder, and the side wall of the clockwork spring is a hollow structure. The spring stent can realize self-expansion and expansion in a blood vessel, effectively adhere to the inner wall of the blood vessel, and can elastically deform according to the memory elasticity to follow the contraction and expansion of the blood vessel, so that a good adhesion effect is achieved. In combination with a pushing assembly included in a stent delivery system and a cutting assembly connected to the distal end of the pushing assembly, the diseased part in the blood vessel can be cut during the implantation of the stent, so that the reliability of the stent adhesion is enhanced, and the risk of new thrombosis and neointimal hyperplasia is reduced.

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).